Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster
Combo Of PARP Inhibitor And J&J's Zytiga Delays Progression In All-Comers
The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.
